Skin Clues That Reveal Hidden Lung Disease in Autoimmune Rheumatic Conditions

Interstitial lung disease (ILD) has quietly become one of the most consequential threats facing patients with systemic autoimmune rheumatic diseases, and a comprehensive new review published in the Archives of Dermatological Research argues that the skin may be the first place clinicians can spot the danger. The review, led by Rachel M. Kirven and colleagues at The Ohio State University Wexner Medical Center, synthesizes decades of evidence on how cutaneous manifestations of six major autoimmune conditions—systemic sclerosis, idiopathic inflammatory myopathies, systemic lupus erythematosus, mixed connective tissue disease, Sjögren’s disease, and systemic vasculitis—track with lung involvement, and it lays out practical screening and referral pathways that could shorten the diagnostic odyssey for thousands of patients.

The central premise is deceptively simple: early ILD is usually subclinical, producing no symptoms while fibrosis and inflammation silently remodel the pulmonary interstitium. Patients, however, often present to dermatologists early in their disease course with rashes, skin thickening, nailfold changes, or ulcers that precede any respiratory complaint. Because radiographic evidence of ILD frequently appears before pulmonary symptoms develop, the dermatologist’s exam room may be the single best early-warning station for lung disease in this population. The authors argue that dermatologists who understand which skin phenotypes and autoantibody profiles signal elevated pulmonary risk can trigger imaging and referral years before a patient ever reports breathlessness.

The technical backbone of ILD evaluation rests on two pillars: pulmonary function testing (PFTs), including spirometry, lung volumes, and diffusing capacity for carbon monoxide (DLCO), and high-resolution computed tomography (HRCT). HRCT remains the diagnostic gold standard because it detects structural lung abnormalities—ground-glass opacities, reticulation, traction bronchiectasis, and honeycombing—before symptoms arise or before chest radiographs and PFTs become abnormal. Current guidelines broadly recommend against substituting PFTs for HRCT when ILD is suspected, a point underscored by data showing that PFTs alone carry a 62 percent false-negative rate at initial screening for systemic sclerosis-associated ILD. The predominant imaging pattern in most of these diseases is nonspecific interstitial pneumonia (NSIP), although usual interstitial pneumonia (UIP) predominates in systemic vasculitis.

Systemic sclerosis illustrates the stakes most vividly. Recent pooled estimates suggest ILD affects approximately 47 percent of patients with the disease, and lung disease—including pulmonary fibrosis—has now replaced renal crisis as the leading cause of scleroderma-related death. The review emphasizes that dermatologic phenotype is tightly linked to pulmonary risk: patients with diffuse cutaneous disease, in which skin thickening extends proximal to the elbows and knees or onto the trunk, face earlier-onset and more progressive ILD than those with limited cutaneous disease. Anti-topoisomerase I (anti-Scl-70) antibodies mark particularly high risk, while anticentromere antibodies, more typical of limited disease, generally predict lower ILD prevalence. Rarer autoantibodies refine the picture further: anti-Th/To is linked to pulmonary fibrosis and hypertension, anti-U11/U12 RNP to severe fibrosis and increased fibrosis-related mortality, anti-PM/Scl to a myositis-overlap phenotype with high pulmonary fibrosis prevalence, and anti-Ro52 to steeper declines in vital capacity over time.

Screening recommendations for systemic sclerosis are now firm. The American College of Rheumatology and the American College of Chest Physicians recommend that every patient with newly diagnosed disease undergo baseline HRCT and PFTs with DLCO, followed by PFTs every three to twelve months for the first three to five years and at least every six to twelve months thereafter. Short-term progression predicts mortality better than baseline severity, making longitudinal monitoring essential. The OMERACT consensus defines clinically meaningful progression as a relative decline in forced vital capacity of at least 10 percent over one year, or a 5 to 10 percent decline accompanied by a 15 percent or greater drop in DLCO—thresholds associated with increased mortality. Novel low-dose HRCT protocols have demonstrated 88 percent sensitivity and 91 percent accuracy in detecting scleroderma-ILD, and emerging data suggest transthoracic lung ultrasound could serve as a non-ionizing adjunct, though neither has yet replaced standard HRCT in guidelines.

The idiopathic inflammatory myopathies present an even more urgent dermatologic challenge. Myositis-specific autoantibodies (MSAs) powerfully predict organ involvement, and several flag severe pulmonary risk. In antisynthetase syndrome, defined by antibodies against aminoacyl-transfer RNA synthetases, as many as 89 percent of antibody-positive patients show some form of ILD, with anti-PL-7 and anti-PL-12 carriers faring worse than those with anti-Jo-1. Dermatomyositis adds its own red flags: the anti-MDA5 antibody, present in a subset of patients with clinically amyopathic dermatomyositis, is 86 percent specific and 77 percent sensitive for rapidly progressive ILD—a catastrophic subtype that worsens within a month despite high-dose corticosteroids, sends 40 to 60 percent of patients to intensive care, and carries a 45 to 51 percent hospital mortality rate. Painful palmar papules, cutaneous and oral ulceration, elevated ferritin, and lymphocytopenia may all predict this trajectory, and the review is unambiguous that such patients warrant urgent pulmonary evaluation.

The remaining conditions show a spectrum of risk. In systemic lupus erythematosus, ILD prevalence is comparatively low at 1 to 15 percent, and five-year mortality of 14.7 percent is better than in other autoimmune ILDs, but Raynaud’s phenomenon, sclerodactyly, and irregular nailfold capillaries can signal radiographic lung involvement—often reflecting overlap syndromes that must be excluded before attributing risk to lupus alone. Mixed connective tissue disease, defined by high-titer anti-U1 RNP antibodies, carries an ILD prevalence estimated at 34 to 66 percent, and even modest lung involvement on HRCT matters: ten-year survival fell from 87 percent in patients with less than 5 percent lung volume involvement to 60 percent in those with more than 10 percent. Nailfold capillaroscopy, showing enlarged capillaries and scleroderma-pattern changes, may help dermatologists identify MCTD patients who need closer pulmonary scrutiny.

Sjögren’s disease and systemic vasculitis round out the picture. A meta-analysis estimated ILD prevalence at roughly 23 percent in primary Sjögren’s, with cumulative incidence climbing to 20 percent within five years of diagnosis; anti-Ro52 positivity raised prevalence to 41.9 percent versus 16.2 percent in antibody-negative patients, and pooled five-year survival among affected patients was 82 percent. Guidelines from both ERS/EULAR and ACR/CHEST recommend risk-based screening with PFTs and HRCT for patients with features such as older age, male sex, Raynaud phenomenon, lymphopenia, and anti-Ro52 positivity, while explicitly rejecting chest radiography and six-minute walk testing as screening tools. In ANCA-associated vasculitis, ILD prevalence reaches as high as 45 percent in microscopic polyangiitis and 23 percent in granulomatosis with polyangiitis—high enough that ILD was added as a classification criterion for MPA in the 2022 ACR/EULAR guidelines. Notably, no major guideline yet defines evidence-based surveillance intervals for vasculitis-associated ILD, a gap the authors highlight as a priority for future research.

The review’s unifying message is that dermatologists occupy a uniquely powerful position in the multidisciplinary care of these patients. By pairing careful skin examination—recognizing Gottron’s papules, heliotrope rash, mechanic’s hands, shawl and V signs, sclerodactyly, calcinosis, and nailfold changes—with targeted autoantibody testing and a focused review of systems probing dyspnea, cough, and exercise intolerance, dermatologists can stratify risk long before respiratory symptoms emerge. Prompt rheumatology referral remains essential for confirming any suspected systemic autoimmune diagnosis, and pulmonary referral is triggered by symptoms, abnormal PFTs, or HRCT findings. As the authors conclude, familiarity with evidence-based screening and monitoring recommendations, and with the specific cutaneous signatures that demand them, is the key to reducing diagnostic delays and getting patients the antifibrotic and immunosuppressive therapies that increasingly can alter the course of autoimmune lung disease.

Subject of Research: Cutaneous manifestations as risk markers for interstitial lung disease in systemic autoimmune rheumatic diseases

Article Title: Cutaneous manifestations of systemic autoimmune rheumatic diseases including systemic sclerosis, idiopathic inflammatory myopathies, systemic lupus erythematous, mixed connective tissue disease, Sjögren’s disease, and systemic vasculitis and the association with interstitial lung disease: a review of dermatologic risk stratification, screening and monitoring guidelines, and indications for pulmonary referral

Article References: Kirven, R. M., Bogunovich, K., Feibel, A. B., Amigo, M., Trovato, S., Massick, S. C., Allen, J., Ajam, A., & Bechtel, M. A. (2026). Cutaneous manifestations of systemic autoimmune rheumatic diseases including systemic sclerosis, idiopathic inflammatory myopathies, systemic lupus erythematous, mixed connective tissue disease, Sjögren’s disease, and systemic vasculitis and the association with interstitial lung disease: a review of dermatologic risk stratification, screening and monitoring guidelines, and indications for pulmonary referral. Archives of Dermatological Research, 318(1), Article 467. https://doi.org/10.1007/s00403-026-04966-0

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04966-0

Keywords: interstitial lung disease, systemic sclerosis, dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease, Sjögren's disease, ANCA-associated vasculitis, autoantibodies, HRCT screening, pulmonary function testing, dermatology, autoimmune rheumatic disease